SE0301431D0 - Novel antimicrobial peptides - Google Patents

Novel antimicrobial peptides

Info

Publication number
SE0301431D0
SE0301431D0 SE0301431A SE0301431A SE0301431D0 SE 0301431 D0 SE0301431 D0 SE 0301431D0 SE 0301431 A SE0301431 A SE 0301431A SE 0301431 A SE0301431 A SE 0301431A SE 0301431 D0 SE0301431 D0 SE 0301431D0
Authority
SE
Sweden
Prior art keywords
antimicrobial
antimicrobial peptide
antimicrobial peptides
amino acid
acid residues
Prior art date
Application number
SE0301431A
Other languages
English (en)
Swedish (sv)
Inventor
Artur Schmidtchen
Original Assignee
Dermagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermagen filed Critical Dermagen
Priority to SE0301431A priority Critical patent/SE0301431D0/xx
Publication of SE0301431D0 publication Critical patent/SE0301431D0/xx
Priority to PL04734024T priority patent/PL1625155T3/pl
Priority to CNB2004800137282A priority patent/CN100362017C/zh
Priority to JP2006517016A priority patent/JP4611979B2/ja
Priority to CN2007101481827A priority patent/CN101161284B/zh
Priority to EP04734024A priority patent/EP1625155B1/en
Priority to ES04734024T priority patent/ES2395206T3/es
Priority to US10/557,455 priority patent/US20070185019A1/en
Priority to CA2523998A priority patent/CA2523998C/en
Priority to AU2004303728A priority patent/AU2004303728B2/en
Priority to KR1020057021961A priority patent/KR101160474B1/ko
Priority to PCT/SE2004/000797 priority patent/WO2005061535A1/en
Priority to US11/877,394 priority patent/US8551954B2/en
Priority to HK08110883.1A priority patent/HK1119390A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723Cationic antimicrobial peptides, e.g. defensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8128Antithrombin III
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SE0301431A 2003-05-19 2003-05-19 Novel antimicrobial peptides SE0301431D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE0301431A SE0301431D0 (sv) 2003-05-19 2003-05-19 Novel antimicrobial peptides
PCT/SE2004/000797 WO2005061535A1 (en) 2003-05-19 2004-05-19 Novel antimicrobial peptides with heparin binding activity
ES04734024T ES2395206T3 (es) 2003-05-19 2004-05-19 Uso de péptidos antimicrobianos con actividad de unión a heparina
CNB2004800137282A CN100362017C (zh) 2003-05-19 2004-05-19 具有肝素结合活性的新的抗微生物肽
JP2006517016A JP4611979B2 (ja) 2003-05-19 2004-05-19 ヘパリン結合活性を有する新規な抗微生物ペプチド
CN2007101481827A CN101161284B (zh) 2003-05-19 2004-05-19 具有肝素结合活性的新的抗微生物肽
EP04734024A EP1625155B1 (en) 2003-05-19 2004-05-19 Use of antimicrobial peptides with heparin binding activity
PL04734024T PL1625155T3 (pl) 2003-05-19 2004-05-19 Zastosowanie peptydów przeciwdrobnoustrojowych o aktywności wiążącej heparynę
US10/557,455 US20070185019A1 (en) 2003-05-19 2004-05-19 Novel antimicrobial peptides with heparin binding activity
CA2523998A CA2523998C (en) 2003-05-19 2004-05-19 Novel antimicrobial peptides
AU2004303728A AU2004303728B2 (en) 2003-05-19 2004-05-19 Novel antimicrobial peptides with heparin binding activity
KR1020057021961A KR101160474B1 (ko) 2003-05-19 2004-05-19 헤파린 결합 활성을 지닌 신규한 항미생물 펩타이드
US11/877,394 US8551954B2 (en) 2003-05-19 2007-10-23 Antimicrobial peptides with heparin binding activity
HK08110883.1A HK1119390A1 (en) 2003-05-19 2008-09-30 Novel antimicrobial peptides with heparin binding activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301431A SE0301431D0 (sv) 2003-05-19 2003-05-19 Novel antimicrobial peptides

Publications (1)

Publication Number Publication Date
SE0301431D0 true SE0301431D0 (sv) 2003-05-19

Family

ID=20291321

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301431A SE0301431D0 (sv) 2003-05-19 2003-05-19 Novel antimicrobial peptides

Country Status (12)

Country Link
US (2) US20070185019A1 (ko)
EP (1) EP1625155B1 (ko)
JP (1) JP4611979B2 (ko)
KR (1) KR101160474B1 (ko)
CN (2) CN100362017C (ko)
AU (1) AU2004303728B2 (ko)
CA (1) CA2523998C (ko)
ES (1) ES2395206T3 (ko)
HK (1) HK1119390A1 (ko)
PL (1) PL1625155T3 (ko)
SE (1) SE0301431D0 (ko)
WO (1) WO2005061535A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0402807D0 (sv) * 2004-11-17 2004-11-17 Dermagen Ab Novel antimicrobial peptides
WO2007091958A1 (en) * 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
EP1987056B1 (en) * 2006-02-10 2012-07-25 Dermagen AB Novel antimicrobial peptides and use thereof
US8227406B2 (en) 2006-05-16 2012-07-24 Dermagen Ab Antimicrobial peptides
WO2008070116A2 (en) * 2006-12-04 2008-06-12 Concert, Llc Topical compositions for treatment of skin conditions
CA2690734A1 (en) * 2007-06-14 2008-12-24 Richard A. Clark Polypeptides and methods of use
GB0821721D0 (en) * 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
WO2010080836A2 (en) 2009-01-06 2010-07-15 C3 Jian, Inc. Antibacterial and antifungal peptides
US8883153B2 (en) * 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
FR2960877B1 (fr) * 2010-06-04 2014-08-29 Agronomique Inst Nat Rech Fraction de proteines et peptides issus du blanc d'oeuf et proteine issue du blanc d'oeuf et leur utilisation comme agent anti-listeria
CN102507936B (zh) * 2011-11-09 2013-10-23 北京正旦国际科技有限责任公司 一种肝癌标志物多抗免疫质谱试剂盒
JP6456819B2 (ja) * 2012-05-14 2019-01-23 メルク パテント ゲーエムベーハー 電気泳動ディスプレイ用の粒子
WO2015138494A1 (en) 2014-03-10 2015-09-17 Georges Belfort Anti-microbial peptides and method for designing novel anti-microbial peptides
WO2017001731A1 (en) * 2015-06-30 2017-01-05 Oulun Yliopisto New antimicrobial peptides, their variants and uses
US11174288B2 (en) * 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
JP2022538903A (ja) * 2019-07-02 2022-09-06 トラスティーズ オブ タフツ カレッジ 細胞および組織への薬剤の送達のための新規ペプチド、組成物および方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5912230A (en) * 1991-11-01 1999-06-15 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
WO1994020532A1 (en) * 1993-03-12 1994-09-15 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5733872A (en) 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
JP3459314B2 (ja) 1994-08-31 2003-10-20 社団法人農林水産技術情報協会 新規ペプチド、抗菌剤、新規ペプチド遺伝子、新規な組み換え体dna及び新規ペプチドの製造法
JPH08208692A (ja) * 1994-09-28 1996-08-13 Sumitomo Pharmaceut Co Ltd 新規な細胞接着抑制ペプチド誘導体
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
IL121134A0 (en) * 1997-06-22 1997-11-20 Yeda Res & Dev Peptides and antiallergic compositions comprising them
IL142822A0 (en) 1998-11-10 2002-03-10 Univ Temple Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
WO2000027415A2 (en) 1998-11-10 2000-05-18 Temple University - Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
US20030083244A1 (en) 2000-04-26 2003-05-01 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
GB2382775B (en) * 2001-12-06 2005-05-25 Johnson & Johnson Medical Ltd Controlled release therapeutic wound dressings
JP2006506969A (ja) * 2002-07-12 2006-03-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン 下垂体アデニル酸シクラーゼ活性化ペプチド(pacap)受容体(vpac2)アゴニストおよびそれらの薬理学的使用方法
US20060173162A1 (en) 2002-08-15 2006-08-03 Rene Djurup Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)

Also Published As

Publication number Publication date
AU2004303728A1 (en) 2005-07-07
EP1625155A1 (en) 2006-02-15
US8551954B2 (en) 2013-10-08
CN1791612A (zh) 2006-06-21
KR101160474B1 (ko) 2012-06-28
CA2523998C (en) 2014-05-13
CN101161284B (zh) 2011-10-05
CA2523998A1 (en) 2005-07-07
PL1625155T3 (pl) 2013-06-28
CN101161284A (zh) 2008-04-16
US20090074864A1 (en) 2009-03-19
JP2007531691A (ja) 2007-11-08
WO2005061535A1 (en) 2005-07-07
US20070185019A1 (en) 2007-08-09
CN100362017C (zh) 2008-01-16
HK1119390A1 (en) 2009-03-06
AU2004303728B2 (en) 2011-03-31
ES2395206T3 (es) 2013-02-11
EP1625155B1 (en) 2012-08-29
JP4611979B2 (ja) 2011-01-12
KR20060028676A (ko) 2006-03-31

Similar Documents

Publication Publication Date Title
SE0301431D0 (sv) Novel antimicrobial peptides
DE60235761D1 (de) Isoform des vegfs
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
ATE368053T1 (de) Antimikrobielle peptide
DE502005006284D1 (de) Keratin-bindende polypeptide
DK0690872T3 (da) Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
HRP20050024A2 (en) Pegylated t20 polypeptide
ATE449790T1 (de) Rekombinante gelatinepartikel für die zelladhäsion
ATE489462T1 (de) Antimikrobielles polypeptid und nutzung davon
BR9914066A (pt) Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
ATE335758T1 (de) Peptidzusammensetzung mit wachstumsfaktor- ähnlicher aktivität
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
ATE110742T1 (de) Peptid-verbindungen.
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
WO2022169913A3 (en) Synthetic degrader system for targeted protein degradation
WO2001034640A3 (de) Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung
DE69615185D1 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
HK1147210A1 (en) Anti-hypertensive agent
WO2003093300A3 (en) Anti-microbial peptides and compositions
ATE390481T1 (de) Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren